A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Identifieur interne : 003454 ( PascalFrancis/Checkpoint ); précédent : 003453; suivant : 003455A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
Auteurs : F. Morschhauser [France] ; J. F. Seymour [Australie] ; H. C. Kluin-Nelemans [Pays-Bas] ; A. Grigg [Australie] ; M. Wolf [Allemagne] ; M. Pfreundschuh [Allemagne] ; H. Tilly [France] ; J. Raemaekers [Pays-Bas] ; M. B. Van T Veer [Pays-Bas] ; N. Milpied [France] ; G. Cartron [France] ; A. Pezzutto [Allemagne] ; A. Spencer [Australie] ; F. Reyes [France] ; M. Dreyling [Allemagne]Source :
- Annals of oncology [ 0923-7534 ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Background: Protein kinase C beta (PKCβ), a pivotal enzyme in B-cell signaling and survival, is overexpressed in most cases of mantle cell lymphoma (MCL). Activation of P13K/AKT pathway is involved in pathogenesis of MCL. Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through PKCβ/P13K/AKT pathways, induces apoptosis, reduces proliferation, and suppresses tumor-induced angiogenesis. Patients and methods: Patients with relapsed/refractory MCL, and no more than four regimens of prior therapy, received 500 mg enzastaurin, orally, once daily. Results: Sixty patients, median age 66 years (range 45-85), Eastern Cooperative Oncology Group performance status of zero to two (48% had baseline International Prognostic Index of 3-5), were enrolled. Most patients had prior CHOP-like chemotherapy and/or rituximab (median = 2 regimens). No drug-related deaths occurred. There was one case each of grade 3 anemia, diarrhea, dyspnea, vomiting, hypotension, and syncope. Fatigue was the most common toxicity. Although no objective tumor responses occurred, 22 patients (37%, 95% Cl 25% to 49%) were free from progression (FFP) for ≥3 cycles (one cycle = 28 days); 6 of 22 were FFP for >6 months. Two patients remain on treatment and FFP at >23 months. Conclusion: Freedom from progression for >6 months in six patients and a favorable toxicity profile with minimal hematological toxicity indicate that enzastaurin warrants evaluation as maintenance therapy and combination chemotherapy in MCL.
Affiliations:
- Allemagne, Australie, France, Pays-Bas
- Berlin, Centre-Val de Loire, District de Kassel, Groningue (province), Gueldre, Haute-Normandie, Hauts-de-France, Hesse (Land), Hollande-Méridionale, Nord-Pas-de-Calais, Pays de la Loire, Région Centre, Région Normandie, Victoria (État), Île-de-France
- Berlin, Cassel (Hesse), Créteil, Groningue (ville), Lille, Melbourne, Nantes, Nimègue, Rotterdam, Rouen, Tours
- Université de Groningue, Université de Melbourne
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:08-0139123Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma</title><author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hematology, Hopital C. Huriez Centre Hospitalier Universitaire</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Seymour, J F" sort="Seymour, J F" uniqKey="Seymour J" first="J. F." last="Seymour">J. F. Seymour</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Hematology, Peter Maccallum Cancer Center, East Melbourne, and University of Melbourne</s1><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Kluin Nelemans, H C" sort="Kluin Nelemans, H C" uniqKey="Kluin Nelemans H" first="H. C." last="Kluin-Nelemans">H. C. Kluin-Nelemans</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Hematology, University Medical Center Groningen, University of Groningen</s1><s3>NLD</s3><sZ>3 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue (ville)</settlement><region>Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author><author><name sortKey="Grigg, A" sort="Grigg, A" uniqKey="Grigg A" first="A." last="Grigg">A. Grigg</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Clinical Hematology and Medical Oncology, Royal Melbourne Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Melbourne, Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Wolf, M" sort="Wolf, M" uniqKey="Wolf M" first="M." last="Wolf">M. Wolf</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Onkologie, Hamatologie, Immunologie, Klinikum Kassel gmbh</s1><s2>Kassel</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Kassel</region><settlement type="city">Cassel (Hesse)</settlement></placeName></affiliation></author><author><name sortKey="Pfreundschuh, M" sort="Pfreundschuh, M" uniqKey="Pfreundschuh M" first="M." last="Pfreundschuh">M. Pfreundschuh</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Onkologie, Hematology, Klin Immunologie & Rheumatologie, Universitatskliniken Des Saarlandes</s1><s2>Homburg/Saar</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Homburg/Saar</wicri:noRegion><wicri:noRegion>Universitatskliniken Des Saarlandes</wicri:noRegion><wicri:noRegion>Homburg/Saar</wicri:noRegion></affiliation></author><author><name sortKey="Tilly, H" sort="Tilly, H" uniqKey="Tilly H" first="H." last="Tilly">H. Tilly</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Centre Henri Becquerel</s1><s2>Rouen</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Région Normandie</region><region type="old region">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Raemaekers, J" sort="Raemaekers, J" uniqKey="Raemaekers J" first="J." last="Raemaekers">J. Raemaekers</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Hematology, University Medical Centre Nijmegen</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Van T Veer, M B" sort="Van T Veer, M B" uniqKey="Van T Veer M" first="M. B." last="Van T Veer">M. B. Van T Veer</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Hematology, Erasmus Medisch Centrum</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Milpied, N" sort="Milpied, N" uniqKey="Milpied N" first="N." last="Milpied">N. Milpied</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Hematology, Chru De Nantes Hotel-Dieu</s1><s2>Nantes</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Cartron, G" sort="Cartron, G" uniqKey="Cartron G" first="G." last="Cartron">G. Cartron</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Hematology, and Cell Therapy, Chru De Tours Hopital Bretonneau</s1><s2>Tours</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author><author><name sortKey="Pezzutto, A" sort="Pezzutto, A" uniqKey="Pezzutto A" first="A." last="Pezzutto">A. Pezzutto</name><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Med Klinic M.S.Hematologie/Oncologie, Universitatsklinikum Charite Med</s1><s2>Berlin</s2><s3>DEU</s3><sZ>12 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Spencer, A" sort="Spencer, A" uniqKey="Spencer A" first="A." last="Spencer">A. Spencer</name><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Hematology and BMT, The Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>13 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Reyes, F" sort="Reyes, F" uniqKey="Reyes F" first="F." last="Reyes">F. Reyes</name><affiliation wicri:level="3"><inist:fA14 i1="14"><s1>Clinical Hematology, Hopital Henri Mondor</s1><s2>Creteil</s2><s3>FRA</s3><sZ>14 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Dreyling, M" sort="Dreyling, M" uniqKey="Dreyling M" first="M." last="Dreyling">M. Dreyling</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Klinikum Grosshadern der Ludwig-Maximillans-Universitat</s1><s2>Munchen</s2><s3>DEU</s3><sZ>15 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Munchen</wicri:noRegion><wicri:noRegion>Klinikum Grosshadern der Ludwig-Maximillans-Universitat</wicri:noRegion><wicri:noRegion>Klinikum Grosshadern der Ludwig-Maximillans-Universitat</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0139123</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0139123 INIST</idno><idno type="RBID">Pascal:08-0139123</idno><idno type="wicri:Area/PascalFrancis/Corpus">003702</idno><idno type="wicri:Area/PascalFrancis/Curation">002937</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003454</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003454</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma</title><author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hematology, Hopital C. Huriez Centre Hospitalier Universitaire</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Seymour, J F" sort="Seymour, J F" uniqKey="Seymour J" first="J. F." last="Seymour">J. F. Seymour</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Hematology, Peter Maccallum Cancer Center, East Melbourne, and University of Melbourne</s1><s3>AUS</s3><sZ>2 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Kluin Nelemans, H C" sort="Kluin Nelemans, H C" uniqKey="Kluin Nelemans H" first="H. C." last="Kluin-Nelemans">H. C. Kluin-Nelemans</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Hematology, University Medical Center Groningen, University of Groningen</s1><s3>NLD</s3><sZ>3 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue (ville)</settlement><region>Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation></author><author><name sortKey="Grigg, A" sort="Grigg, A" uniqKey="Grigg A" first="A." last="Grigg">A. Grigg</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Clinical Hematology and Medical Oncology, Royal Melbourne Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Melbourne, Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Wolf, M" sort="Wolf, M" uniqKey="Wolf M" first="M." last="Wolf">M. Wolf</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Onkologie, Hamatologie, Immunologie, Klinikum Kassel gmbh</s1><s2>Kassel</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Kassel</region><settlement type="city">Cassel (Hesse)</settlement></placeName></affiliation></author><author><name sortKey="Pfreundschuh, M" sort="Pfreundschuh, M" uniqKey="Pfreundschuh M" first="M." last="Pfreundschuh">M. Pfreundschuh</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Onkologie, Hematology, Klin Immunologie & Rheumatologie, Universitatskliniken Des Saarlandes</s1><s2>Homburg/Saar</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Homburg/Saar</wicri:noRegion><wicri:noRegion>Universitatskliniken Des Saarlandes</wicri:noRegion><wicri:noRegion>Homburg/Saar</wicri:noRegion></affiliation></author><author><name sortKey="Tilly, H" sort="Tilly, H" uniqKey="Tilly H" first="H." last="Tilly">H. Tilly</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Centre Henri Becquerel</s1><s2>Rouen</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Région Normandie</region><region type="old region">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Raemaekers, J" sort="Raemaekers, J" uniqKey="Raemaekers J" first="J." last="Raemaekers">J. Raemaekers</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Hematology, University Medical Centre Nijmegen</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>8 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Van T Veer, M B" sort="Van T Veer, M B" uniqKey="Van T Veer M" first="M. B." last="Van T Veer">M. B. Van T Veer</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Hematology, Erasmus Medisch Centrum</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Milpied, N" sort="Milpied, N" uniqKey="Milpied N" first="N." last="Milpied">N. Milpied</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Hematology, Chru De Nantes Hotel-Dieu</s1><s2>Nantes</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Cartron, G" sort="Cartron, G" uniqKey="Cartron G" first="G." last="Cartron">G. Cartron</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Hematology, and Cell Therapy, Chru De Tours Hopital Bretonneau</s1><s2>Tours</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Tours</settlement></placeName></affiliation></author><author><name sortKey="Pezzutto, A" sort="Pezzutto, A" uniqKey="Pezzutto A" first="A." last="Pezzutto">A. Pezzutto</name><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Med Klinic M.S.Hematologie/Oncologie, Universitatsklinikum Charite Med</s1><s2>Berlin</s2><s3>DEU</s3><sZ>12 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Spencer, A" sort="Spencer, A" uniqKey="Spencer A" first="A." last="Spencer">A. Spencer</name><affiliation wicri:level="3"><inist:fA14 i1="13"><s1>Hematology and BMT, The Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>13 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Reyes, F" sort="Reyes, F" uniqKey="Reyes F" first="F." last="Reyes">F. Reyes</name><affiliation wicri:level="3"><inist:fA14 i1="14"><s1>Clinical Hematology, Hopital Henri Mondor</s1><s2>Creteil</s2><s3>FRA</s3><sZ>14 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Dreyling, M" sort="Dreyling, M" uniqKey="Dreyling M" first="M." last="Dreyling">M. Dreyling</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Klinikum Grosshadern der Ludwig-Maximillans-Universitat</s1><s2>Munchen</s2><s3>DEU</s3><sZ>15 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Munchen</wicri:noRegion><wicri:noRegion>Klinikum Grosshadern der Ludwig-Maximillans-Universitat</wicri:noRegion><wicri:noRegion>Klinikum Grosshadern der Ludwig-Maximillans-Universitat</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Annals of oncology</title><title level="j" type="abbreviated">Ann. oncol.</title><idno type="ISSN">0923-7534</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of oncology</title><title level="j" type="abbreviated">Ann. oncol.</title><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>B cell neoplasm</term><term>B-Lymphocyte</term><term>Enzastaurin</term><term>Human</term><term>Inhibitor</term><term>Mantle cell lymphoma</term><term>Phase II trial</term><term>Protein kinase C</term><term>Protein kinase Cβ</term><term>Relapse</term><term>Treatment</term><term>Treatment resistance</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Essai clinique phase II</term><term>Traitement</term><term>Enzastaurine</term><term>Protein kinase C</term><term>Inhibiteur</term><term>Récidive</term><term>Résistance traitement</term><term>Lymphome centrocytique</term><term>Lymphocyte B</term><term>Protein kinase Cβ</term><term>Hémopathie lymphoïde B</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Protein kinase C beta (PKCβ), a pivotal enzyme in B-cell signaling and survival, is overexpressed in most cases of mantle cell lymphoma (MCL). Activation of P13K/AKT pathway is involved in pathogenesis of MCL. Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through PKCβ/P13K/AKT pathways, induces apoptosis, reduces proliferation, and suppresses tumor-induced angiogenesis. Patients and methods: Patients with relapsed/refractory MCL, and no more than four regimens of prior therapy, received 500 mg enzastaurin, orally, once daily. Results: Sixty patients, median age 66 years (range 45-85), Eastern Cooperative Oncology Group performance status of zero to two (48% had baseline International Prognostic Index of 3-5), were enrolled. Most patients had prior CHOP-like chemotherapy and/or rituximab (median = 2 regimens). No drug-related deaths occurred. There was one case each of grade 3 anemia, diarrhea, dyspnea, vomiting, hypotension, and syncope. Fatigue was the most common toxicity. Although no objective tumor responses occurred, 22 patients (37%, 95% Cl 25% to 49%) were free from progression (FFP) for ≥3 cycles (one cycle = 28 days); 6 of 22 were FFP for >6 months. Two patients remain on treatment and FFP at >23 months. Conclusion: Freedom from progression for >6 months in six patients and a favorable toxicity profile with minimal hematological toxicity indicate that enzastaurin warrants evaluation as maintenance therapy and combination chemotherapy in MCL.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0923-7534</s0></fA01><fA03 i2="1"><s0>Ann. oncol.</s0></fA03><fA05><s2>19</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma</s1></fA08><fA11 i1="01" i2="1"><s1>MORSCHHAUSER (F.)</s1></fA11><fA11 i1="02" i2="1"><s1>SEYMOUR (J. F.)</s1></fA11><fA11 i1="03" i2="1"><s1>KLUIN-NELEMANS (H. C.)</s1></fA11><fA11 i1="04" i2="1"><s1>GRIGG (A.)</s1></fA11><fA11 i1="05" i2="1"><s1>WOLF (M.)</s1></fA11><fA11 i1="06" i2="1"><s1>PFREUNDSCHUH (M.)</s1></fA11><fA11 i1="07" i2="1"><s1>TILLY (H.)</s1></fA11><fA11 i1="08" i2="1"><s1>RAEMAEKERS (J.)</s1></fA11><fA11 i1="09" i2="1"><s1>VAN 'T VEER (M. B.)</s1></fA11><fA11 i1="10" i2="1"><s1>MILPIED (N.)</s1></fA11><fA11 i1="11" i2="1"><s1>CARTRON (G.)</s1></fA11><fA11 i1="12" i2="1"><s1>PEZZUTTO (A.)</s1></fA11><fA11 i1="13" i2="1"><s1>SPENCER (A.)</s1></fA11><fA11 i1="14" i2="1"><s1>REYES (F.)</s1></fA11><fA11 i1="15" i2="1"><s1>DREYLING (M.)</s1></fA11><fA14 i1="01"><s1>Hematology, Hopital C. Huriez Centre Hospitalier Universitaire</s1><s2>Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Hematology, Peter Maccallum Cancer Center, East Melbourne, and University of Melbourne</s1><s3>AUS</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Hematology, University Medical Center Groningen, University of Groningen</s1><s3>NLD</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Clinical Hematology and Medical Oncology, Royal Melbourne Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Onkologie, Hamatologie, Immunologie, Klinikum Kassel gmbh</s1><s2>Kassel</s2><s3>DEU</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Onkologie, Hematology, Klin Immunologie & Rheumatologie, Universitatskliniken Des Saarlandes</s1><s2>Homburg/Saar</s2><s3>DEU</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Centre Henri Becquerel</s1><s2>Rouen</s2><s3>FRA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Hematology, University Medical Centre Nijmegen</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>Hematology, Erasmus Medisch Centrum</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>9 aut.</sZ></fA14><fA14 i1="10"><s1>Hematology, Chru De Nantes Hotel-Dieu</s1><s2>Nantes</s2><s3>FRA</s3><sZ>10 aut.</sZ></fA14><fA14 i1="11"><s1>Hematology, and Cell Therapy, Chru De Tours Hopital Bretonneau</s1><s2>Tours</s2><s3>FRA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="12"><s1>Med Klinic M.S.Hematologie/Oncologie, Universitatsklinikum Charite Med</s1><s2>Berlin</s2><s3>DEU</s3><sZ>12 aut.</sZ></fA14><fA14 i1="13"><s1>Hematology and BMT, The Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>13 aut.</sZ></fA14><fA14 i1="14"><s1>Clinical Hematology, Hopital Henri Mondor</s1><s2>Creteil</s2><s3>FRA</s3><sZ>14 aut.</sZ></fA14><fA14 i1="15"><s1>Klinikum Grosshadern der Ludwig-Maximillans-Universitat</s1><s2>Munchen</s2><s3>DEU</s3><sZ>15 aut.</sZ></fA14><fA20><s1>247-253</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>22429</s2><s5>354000161905310080</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>40 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0139123</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Annals of oncology</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Protein kinase C beta (PKCβ), a pivotal enzyme in B-cell signaling and survival, is overexpressed in most cases of mantle cell lymphoma (MCL). Activation of P13K/AKT pathway is involved in pathogenesis of MCL. Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through PKCβ/P13K/AKT pathways, induces apoptosis, reduces proliferation, and suppresses tumor-induced angiogenesis. Patients and methods: Patients with relapsed/refractory MCL, and no more than four regimens of prior therapy, received 500 mg enzastaurin, orally, once daily. Results: Sixty patients, median age 66 years (range 45-85), Eastern Cooperative Oncology Group performance status of zero to two (48% had baseline International Prognostic Index of 3-5), were enrolled. Most patients had prior CHOP-like chemotherapy and/or rituximab (median = 2 regimens). No drug-related deaths occurred. There was one case each of grade 3 anemia, diarrhea, dyspnea, vomiting, hypotension, and syncope. Fatigue was the most common toxicity. Although no objective tumor responses occurred, 22 patients (37%, 95% Cl 25% to 49%) were free from progression (FFP) for ≥3 cycles (one cycle = 28 days); 6 of 22 were FFP for >6 months. Two patients remain on treatment and FFP at >23 months. Conclusion: Freedom from progression for >6 months in six patients and a favorable toxicity profile with minimal hematological toxicity indicate that enzastaurin warrants evaluation as maintenance therapy and combination chemotherapy in MCL.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02R</s0></fC02><fC02 i1="02" i2="X"><s0>002B19B</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Human</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Essai clinique phase II</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Phase II trial</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Enzastaurine</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Enzastaurin</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Enzastaurina</s0><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Protein kinase C</s0><s2>FE</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Protein kinase C</s0><s2>FE</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Protein kinase C</s0><s2>FE</s2><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Inhibiteur</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Inhibitor</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Inhibidor</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Récidive</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Relapse</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Recaida</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Résistance traitement</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Treatment resistance</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Resistencia tratamiento</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Lymphome centrocytique</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Mantle cell lymphoma</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Linfoma centrocítico</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Lymphocyte B</s0><s5>23</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>B-Lymphocyte</s0><s5>23</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Linfocito B</s0><s5>23</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Protein kinase Cβ</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Protein kinase Cβ</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Hémopathie lymphoïde B</s0><s4>CD</s4><s5>98</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>B cell neoplasm</s0><s4>CD</s4><s5>98</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Transferases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Hémopathie maligne</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Malignant hemopathy</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Hemopatía maligna</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Lymphome non hodgkinien</s0><s5>38</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Non Hodgkin lymphoma</s0><s5>38</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Linfoma no Hodgkin</s0><s5>38</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0><s2>NM</s2><s5>39</s5></fC07><fN21><s1>084</s1></fN21></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Pays-Bas</li></country><region><li>Berlin</li><li>Centre-Val de Loire</li><li>District de Kassel</li><li>Groningue (province)</li><li>Gueldre</li><li>Haute-Normandie</li><li>Hauts-de-France</li><li>Hesse (Land)</li><li>Hollande-Méridionale</li><li>Nord-Pas-de-Calais</li><li>Pays de la Loire</li><li>Région Centre</li><li>Région Normandie</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Berlin</li><li>Cassel (Hesse)</li><li>Créteil</li><li>Groningue (ville)</li><li>Lille</li><li>Melbourne</li><li>Nantes</li><li>Nimègue</li><li>Rotterdam</li><li>Rouen</li><li>Tours</li></settlement><orgName><li>Université de Groningue</li><li>Université de Melbourne</li></orgName></list><tree><country name="France"><region name="Hauts-de-France"><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F." last="Morschhauser">F. Morschhauser</name></region><name sortKey="Cartron, G" sort="Cartron, G" uniqKey="Cartron G" first="G." last="Cartron">G. Cartron</name><name sortKey="Milpied, N" sort="Milpied, N" uniqKey="Milpied N" first="N." last="Milpied">N. Milpied</name><name sortKey="Reyes, F" sort="Reyes, F" uniqKey="Reyes F" first="F." last="Reyes">F. Reyes</name><name sortKey="Tilly, H" sort="Tilly, H" uniqKey="Tilly H" first="H." last="Tilly">H. Tilly</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Seymour, J F" sort="Seymour, J F" uniqKey="Seymour J" first="J. F." last="Seymour">J. F. Seymour</name></region><name sortKey="Grigg, A" sort="Grigg, A" uniqKey="Grigg A" first="A." last="Grigg">A. Grigg</name><name sortKey="Spencer, A" sort="Spencer, A" uniqKey="Spencer A" first="A." last="Spencer">A. Spencer</name></country><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Kluin Nelemans, H C" sort="Kluin Nelemans, H C" uniqKey="Kluin Nelemans H" first="H. C." last="Kluin-Nelemans">H. C. Kluin-Nelemans</name></region><name sortKey="Raemaekers, J" sort="Raemaekers, J" uniqKey="Raemaekers J" first="J." last="Raemaekers">J. Raemaekers</name><name sortKey="Van T Veer, M B" sort="Van T Veer, M B" uniqKey="Van T Veer M" first="M. B." last="Van T Veer">M. B. Van T Veer</name></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Wolf, M" sort="Wolf, M" uniqKey="Wolf M" first="M." last="Wolf">M. Wolf</name></region><name sortKey="Dreyling, M" sort="Dreyling, M" uniqKey="Dreyling M" first="M." last="Dreyling">M. Dreyling</name><name sortKey="Pezzutto, A" sort="Pezzutto, A" uniqKey="Pezzutto A" first="A." last="Pezzutto">A. Pezzutto</name><name sortKey="Pfreundschuh, M" sort="Pfreundschuh, M" uniqKey="Pfreundschuh M" first="M." last="Pfreundschuh">M. Pfreundschuh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003454 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 003454 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:08-0139123
|texte= A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
}}
| This area was generated with Dilib version V0.6.33. |  |